Professor Joanna Porter was delighted to be awarded over £2M from LifeArc to run two clinical trials in COVID-19.
The first, ATTRACT, is in collaboration with Vicore Pharma, whom we have worked with for over 10 years on developing novel approaches for pulmonary fibrosis. The drug, VP01 (Compound 21; C21) is hoped to recalibrate the renin-angiotensin- system towards repair rather than inflammation. This should indirectly help our research into pulmonary fibrosis too.
The second study, COVASE, is a collaboration with Veni Papayannopoulos and Veronique Brilaut at The Francis Crick Institute, to investigate an approved nebulised recombinant human deoxyribonuclease I (Dornase alfa) to reduce hyperinflammation from neutrophil extracellular traps in the lungs of hospitalised participants with COVID-19.
ATTRACT is open to recruitment and COVASE will open in the next two weeks.
Here’s the LifeArc press release with more info: https://www.lifearc.org/funding/covid-19-funding/
Recent Articles
- ERJ Publication: Mortality markers in CPFE
- Multiorgan MRI findings after hospitalisation with COVID-19
- Breathing Techniques
- Winter Wellness
- Get your Tickets for our Christmas Charity Concert
- London Landmarks Half Marathon
- Air Pollution is Harming our Lungs
- You Helped Us Raise Awareness During #Breathtember
- Christmas Concert at St Pancras Church
- September 2023 Newsletter
- Fundraiser in memory of our forefather, Lawrence Matz
- Step Up for #Breathtember, Pulmonary Fibrosis Awareness Month
- Celebrate World Bronchiectasis Day
- Respiratory Health Campaign
- June 2023 Newsletter